Bevacizumab and invasive procedures: Practical recommendations;Bevacizumab et actes invasifs: Recommandations pratiques

Revue des Maladies Respiratoires

Volumn 26, Issue 2, 2009, Pages 221-226

  Gounant, V ^a   Milleron, B ^a   Assouad, J ^a   Gligorov, J ^a   Lavole, A ^a   Wislez, M ^a   Brian, E ^a   Bazelly, B ^a   Grunenwald, D ^a  

^a HÔPITAL TENON   (France)

Author keywords

Bevacizumab; Non small cell lung cancer; Recommendations; Secondary effects; Surgery

Indexed keywords

BEVACIZUMAB;

ANTIANGIOGENIC THERAPY; BLEEDING TENDENCY; CANCER ADJUVANT THERAPY; COLORECTAL CARCINOMA; HUMAN; INVASIVE PROCEDURE; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; PATIENT REFERRAL; PREOPERATIVE TREATMENT; REVIEW; RISK ASSESSMENT; SCAR FORMATION; SURGICAL RISK; THERAPY DELAY; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 62249153999     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(09)71598-0     Document Type: Review

References (19)

1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
2. Berry S, Michael M, Kretzschmar A, Cunningham D, Di Bartolomeo M, Rivera F, Lutiger B, Mazier M, Van Cutsem E: Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: Preliminary results from first BEAT. Proceedings of 2006 Grastrointestinal Cancers Symposium. Abstract 245 (abstract).
3. Kretzschmar A, Berry S, Cunningham D, Di Bartolomeo M, Kosmidis PA, Michael M, Vegas-Villegas ME, Lutiger B, Mazier MA, Van Cutsem: Starting bevacizumab shortly after venous access device implantation appears not to increase wound healing/bleeding complications nor catheter related thromboses - preliminary results from first BEAT. Eur J Cancer Sup 2005 ; 3 : 177 (abstract).
4. Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC: Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer drugs 2008 ; 19 : 217-9.
5. Cho YJ, Murgu SD, Colt HG: Bronchoscopy for bevacizumab-related hemoptysis. Lung cancer 2007 ; 56 : 465-8.
6. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenis inhibitors, a review. Eur J Cancer 2006 ; 42 : 3127-39.
7. Howdieshell TR, Callaway D, Webb WL, Gaines MD, Proctor CD, Jr., Sathyanarayana, Pollock JS, Brock TL, McNeil PL: Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001 ; 96 : 173-82.
8. Zhang F, Lei MP, Oswald TM, Pang Y, Blain B, Cai ZW, Lineaweaver WC: The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 2003 ; 56 : 334-41.
9. Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002 ; 105 : 43-7.
10. Ellis LM, Curley SA, Grothey A: Surgical rescction after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005 ; 23 : 4853-5.
11. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giulante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007 ; 43 : 2037-45.
12. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 ; 19 : 843-50.
13. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, odriguez-Bigas MA, Curley SA, Feig BW: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008 ; 26 : 5254-60.
14. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008 ; 206 : 96-106.
15. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008 ; 26 : 1830-5.
16. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or rescetion of locally recurrent renal cell carcinoma. J Urol 2008 ; 180 : 94-8.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovirin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
18. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005 ; 91 : 173-80.
19. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, De Matteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007 ; 14 : 759-65.